[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Kuwait\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":670},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,40,65,95,131,167,189,219,247,269,299,322,341,363,390,415,442,469,499,524,557,587,610,636],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100609545","a-real-world-study-to-evaluate-luspatercept-in-adults-with-transfusion-dependent-beta-thalassemia-in-the-middle-east-100609545",false,"NCT07215975","A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East","REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study","Inclusion Criteria:\n\n* Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment\n* Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).\n* Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.\n* Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.\n* Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study\n\nExclusion Criteria:\n\n* Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC.\n* Participants who are currently receiving or are planned to receive treatment with any investigational drug\u002Fdevice\u002Fintervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation.\n* Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period.\n* Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East",[24],"β-thalassemia",[26],"Transfusion-dependent β-thalassemia","RECRUITING","2026-08-18",{"date":30,"type":31},"2026-08-19","ACTUAL",{"date":33,"type":31},"2026-06-26",{"date":35,"type":20},"2031-04-17",{"name":37,"class":38},"Bristol-Myers Squibb","INDUSTRY",13,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100595901","early-detection-of-type-1-diabetes-in-first-degree-relatives-of-type-1-diabetes-patients-detect-t1d-gulf-100595901","NCT07038473","Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)","Islet Autoantibody Early Detection in At-risk Children\u002FAdolescents to Predict Type 1 Diabetes: a Cohort Study in Gulf Countries","Inclusion Criteria:\n\n* Children and adolescents, age 1.5 years to 18 years\n* First degree relatives of T1D probands\n* Parent or legal guardian signing an informed consent\n\nExclusion Criteria:\n\n* Already developed clinical overt T1D\n* Known diabetes of any kind (type 1, type 2, Maturity Onset Diabetes of the Young - MODY)\n* Have a previous history of being treated with insulin\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",true,"18 Months",{"count":50,"type":20},3500,"INTERVENTIONAL",[53],"NA","The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D. This protocol has been developed to address the growing need for standardized T1D screening, monitoring, and data collection in alignment with international recommendations. The study's estimated duration is 13 months and will consist of two visits: Visit 1 (screening visit) and Visit 2 (confirmatory visit).",[56],"Type 1 Diabetes",{"date":30,"type":31},{"date":59,"type":31},"2025-12-17",{"date":61,"type":20},"2026-12-25",{"name":63,"class":38},"Sanofi",7,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100078039","product-performance-report-evaluate-long-term-reliability--performance-of-medtronic-marketed-cardiac-therapy-products-100078039","NCT00271180","Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products","Medtronic CRDM Product Performance Report","PPR","Subjects who meet the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment.\n\nInclusion Criteria:\n\n• Subject or appropriate legal guardians provide written informed consent and\u002For authorization for access to and use of health information as required by an institution's IRB\u002FMEC\u002FREB\n\nAND one of the following must also apply:\n\n* Subject is indicated for implant or within 30 days post-implant of at least one Medtronic market-released product used for a pacing, sensing or defibrillation application\n* Subjects who participated in a qualifying study (IDE) of a Medtronic market-released product with complete implant and follow-up data and subject or appropriate legal guardian authorizes release of subject study data\n\nExclusion Criteria:\n\n* Subjects who are, or will be inaccessible for follow-up\n* Subjects with exclusion criteria required by local law (EMEA only)\n* Subjects receiving an implant of a Medtronic device at a non-participating center and the implant data and current status cannot be confirmed within 30 days after implant\n* Subjects implanted with a Medtronic device whose predetermined enrollment limit for that specific product has been exceeded",{"count":74,"type":20},20000,"The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.",[77,78,79,80],"Arrhythmia","Bradycardia","Heart Failure","Sinus Tachycardia",[82,83,84,85],"Cardiac Pacing","Implantable Cardioverter Defibrillator","pacemaker","Sinus Bradycardia",{"date":87,"type":31},"2026-08-20",{"date":89,"type":31},"1983-01",{"date":91,"type":20},"2040-12",{"name":93,"class":38},"Medtronic",333,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100172884","product-surveillance-registry-100172884","NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results",{"count":104,"type":20},100000,"The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","2026-08-17",{"date":28,"type":31},{"date":126,"type":4},"2012-01",{"date":128,"type":20},"2040-01",{"name":93,"class":38},400,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":47,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":51,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":166},"100651832","feasibility-and-uptake-of-low-dose-ct-lung-cancer-screening-in-kuwait-100651832","NCT07766538","Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait","ALIA Kuwait: A Prospective Pilot Feasibility Study of Low-Dose Computed Tomography Screening for Lung Cancer in High-Risk Individuals in Kuwait","ALIA","Inclusion Criteria:\n\n* Age 50 to 80 years\n* Smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conventions (1 shisha head-year = 1 pack-year; 1 cigar = 4 cigarettes; 1 pipe bowl = 2.5 cigarettes; roll-your-own tobacco 1 g = 1 cigarette). Current and former smokers are eligible regardless of time since quitting.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous diagnosis of lung cancer\n* Currently under surveillance for pulmonary nodules\n* Currently undergoing diagnostic assessment, treatment, or surveillance for major comorbidities\n* Unable to lie flat with arms raised above the head for CT scanning\n* Symptoms suggestive of lung cancer (persistent or worsening cough, haemoptysis, or unexplained weight loss of more than 7 kg in the past year)","50 Years","80 Years",{"count":142,"type":20},500,[53],"Lung cancer is a leading cause of cancer-related death in Kuwait, where most cases are diagnosed at an advanced stage and there is no national screening program. This prospective pilot feasibility study will offer low-dose computed tomography (LDCT) screening to approximately 500 high-risk individuals aged 50-80 years across Kuwait. The primary objective is to assess the uptake of, and barriers to, LDCT lung cancer screening in Kuwait and to establish a framework for a national screening program. Participants undergo eligibility assessment (smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conversions for shisha\u002Fwaterpipe, cigar, pipe, and roll-your-own tobacco), baseline assessment, LDCT screening with Lung-RADS-based management, a second screening round at 12 months, and follow-up. LDCT images are read by radiologists and in parallel by artificial intelligence (AI) software to evaluate AI-assisted reading. Findings will inform national lung cancer screening guidelines for Kuwait.",[146,147],"Lung Cancer","Lung Neoplasms",[149,150,151,152,153,154,155],"lung cancer screening","low-dose computed tomography","Lung-RADS","artificial intelligence","shisha waterpipe smoking","Kuwait","pilot feasibility study","NOT_YET_RECRUITING","2026-08-14",{"date":123,"type":31},{"date":160,"type":20},"2026-09-01",{"date":162,"type":20},"2029-08-31",{"name":164,"class":165},"Sulaiman Khadadah","OTHER_GOV",1,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":188},"100550119","extubation-related-complications---the-extube-study-extube-100550119","NCT06442930","EXtubation Related Complications - the EXTUBE Study (EXTUBE)","EXtubation Related Complications - an International Observational Study To Understand the Impact and BEst Practices in the Operating Room and Intensive Care Unit - the EXTUBE Study","EXTUBE","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Undergoing extubation of an endotracheal tube (including index extubation and re-extubations) after general anesthesia in the OR, out of OR anesthesia location or ICU\n* Undergoing extubation during the specified enrollment window\n\nExclusion Criteria:\n\n* Patients will be excluded if the extubation is performed in the context of withdrawal of life support measures,\n* Patients will be excluded if the extubation is performed for tracheostomy decannulation\n\nFor each patient who is not included, reasons for exclusion will be reported.",{"count":176,"type":20},3000,"EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general anesthesia or after critical illness in the operating room (OR), out of OR anesthesia location or intensive care unit (ICU).",[179],"Extubation",{"date":123,"type":31},{"date":182,"type":31},"2025-04-14",{"date":184,"type":20},"2027-12",{"name":186,"class":187},"University Health Network, Toronto","OTHER",34,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":51,"phases":200,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100544898","phase-4-fibrosis-lessens-after-metabolic-surgery-100544898","NCT06374875","Fibrosis Lessens After Metabolic Surgery","A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis","FLAMES","Inclusion Criteria\n\nEntry into the study would require that the patient:\n\n1. Is a candidate for general anesthesia\n2. Is eligible for metabolic surgery (RYGB or SG) based on the ASMBS\u002FIFSO 2022 guidelines\n3. Has insurance coverage for metabolic surgery (the requirements may vary in each country)\n4. Is ≥18 and ≤75 years old at the time of signing the informed consent\n5. Has a BMI ≥35 and ≤70 kg\u002Fm2 at the time of first study visit\n6. FIB-4 ≥ 1.3\n7. At least one of the following 5 criteria suggesting presence of advanced fibrosis:\n\n   * LSM ≥ 12 kPa by VCTE using FibroScan®\n   * LSM ≥ 12 kPa by SWE\n   * LSM ≥ 1.7 m\u002Fs by ARFI\n   * LSM ≥ 3.63 kPa MRE\n   * ELF score ≥ 9.8\n8. Patients with and without T2DM are eligible for the study. Patients with T2DM should have been on a stable dose of anti-diabetic medication (including insulin but not semaglutide or tirzepatide or liraglutide) for at least 3 months prior to entry, with glycated hemoglobin (HbA1c) ≤12%.\n9. Self-reported stable weight in 6 months before the first study visit (no weight loss \\>10% within 6 months prior to the first study visit)\n\n   a. In patients with a historical noninvasive tests or liver biopsy, weight loss of no more than 10% is allowed from 6 months prior to the historical tests until the first study visit\n10. Has the ability and willingness to participate in the study, provide informed consent, and agree to any of the arms involved in the study\n11. Can understand the options and comply with the requirements of each arm, including one liver biopsy performed during the screening period (if no adequate biopsy within 12 months before screening is available) and one liver biopsy after 2-years\n12. Has a negative urine pregnancy test at the first and at the randomization visits for women of childbearing potential.\n13. Women of childbearing age must agree to use reliable method of contraception for 2 years\n\n8.2 Exclusion Criteria\n\nPatients who meet the following criteria will be excluded from the study:\n\n1. Known history of other chronic liver diseases (drug induced, viral hepatitis, autoimmune, and genetic):\n\n   * Hepatitis B as detected by presence of hepatitis B surface antigen (HBsAg)\n   * Hepatitis C as detected by presence of hepatitis C virus (HCV) RNA (in case the screening test for hepatitis C is positive, the confirmative test is decisive)\n   * Autoimmune liver disease as diagnosed by antibodies or compatible liver histology\n   * Primary biliary cirrhosis as defined by the presence of at least 2 criteria (elevated alkaline phosphatase, presence of anti-mitochondrial antibody, and histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)\n   * Primary sclerosing cholangitis\n   * Wilson's disease as diagnosed by low ceruloplasmin or compatible liver histology\n   * Alpha-1-antitrypsin deficiency as diagnosed by alpha1-antitrypsin level or liver histology\n   * Hemochromatosis as diagnosed by HFE mutations (C282Y, H63D), ferritin and transferrin saturation levels, or presence of 3+ or 4+ stainable iron on liver biopsy\n   * Drug-induced liver disease diagnosed by medical history\n   * Known bile duct obstruction\n   * Suspected or proven liver cancer\n2. Weight change \\>10% within 6 months prior to the first study visit or prior to the historical liver biopsy\n3. Treatment with semaglutide, tirzepatide, or liraglutide (for obesity or for T2DM) \\\u003C90 days before the first study visit.\n\n   • However, patients are allowed to participate if they have been on a low dose (or are on older generation GLP-1 agonists) and have lost less than 10% of their body weight since starting the medication.\n4. Type 1 diabetes or autoimmune diabetes\n5. Known cases of human immunodeficiency virus infection\n6. Prior bariatric and metabolic surgery of any kind\n\n   • Reversed procedures such as gastric band or intragastric balloon that have been removed at least 3 months prior to the first study visit are allowed.\n7. Prior complex foregut surgery including any esophageal and gastric surgeries, anti-reflux procedures, biliary diversion, and complex trauma surgery\n8. Any surgery requiring general anesthesia within 1 month prior to signing the consent\n9. History of solid organ transplant\n10. Severe pulmonary disease defined as FEV1 \\\u003C 50% of predicted value\n11. Significant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)\n12. Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V\n13. Classified as New York Heart Association Class IV\n14. Left ventricular ejection fraction \\\u003C25% at the time of screening\n15. Myocardial infarction, unstable angina, stroke, heart surgery, coronary stent placement in the past 6 months\n16. Chronic renal insufficiency with eGFR below 30 mL\u002Fmin\u002F1.73 m2, or being on dialysis\n17. Presence of large hiatal hernia (\\>7 cm)\n18. Presence of Crohn's disease\n19. Psychiatric disorders including (but not limited to) dementia, active psychosis, severe depression requiring 3 or more medications, history of suicide attempts, active alcohol, or substance abuse within the previous 12 months that in the opinion of the investigators could disqualify the patient from metabolic surgery\n20. Pregnancy, the intention of becoming pregnant, or not using adequate contraceptive measures\n21. Breastfeeding\n22. Diagnosis of malignancy within the preceding 3 years (except squamous cell and basal cell cancer of the skin)\n23. Anemia defined as hemoglobin less than 9 g\u002FdL\n24. On therapeutic dose of anticoagulants such as warfarin or direct oral anticoagulants (DOACs)\n25. Known history of clotting disorders, including pulmonary embolus and deep vein thrombosis\n26. Clinical judgment that life expectancy is less than 3 years\n27. Use of investigational therapy within 3 months prior to signing the consent\n28. History of pancreatic carcinoma\n29. Acute pancreatitis \\\u003C 180 days before screening\n30. History or presence of chronic pancreatitis\n31. Presence of concerning thyroid nodule\n32. Uncontrolled thyroid disease: thyroid stimulating hormone (TSH) \\> 6.0 mIU\u002FL or \\\u003C 0.1 mIU\u002FL before the first study visit\n\n    * Patients receiving treatment for hypothyroidism can be included if their thyroid hormone replacement dose has been stable for at least 3 months.\n    * Patients whose TSH is outside the rang but they have normal levels of thyroid hormones can be included.\n33. A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n34. Evidence or history of ascites or spontaneous bacterial peritonitis that require(d) treatment\n\n    • Trace ascites identified only by an abdominal imaging without other evidence of clinically significant portal hypertension and esophageal varices is not an exclusion criterion.\n35. Evidence or history of hepatic encephalopathy\n36. Evidence or history of variceal bleeding\n37. Evidence or history of portosplenic vein thrombosis\n38. Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to the first study visit.\n\n    • Defined as more than 14 units\u002Fweek for females (\\>1 drink per day) and more than 21 units\u002Fweek for males (\\>2 drinks per day) on average, where one unit of alcohol is equivalent to a 12-oz beer, 4-ounce glass of wine, or 1-ounce shot of hard liquor.\n39. Treatment with medications (for more than 14 consecutive days) with known effect on liver steatosis (e.g., treatment with systemic corticosteroids \\[oral or intravenous\\], methotrexate, tamoxifen, valproic acid, amiodarone, or tetracycline) in the 3 months prior to the first study visit (or historical liver biopsy).\n40. ALT or AST or Alkaline phosphatase \\>200 U\u002FL\n41. Recurrent major hypoglycemia or hypoglycemic unawareness\n42. Inability to safely obtain a liver biopsy\n43. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study\n44. Unable to understand the risks, benefits, and compliance requirements of study\n45. Lack capacity to give informed consent\n46. Plans to move outside the primary location of study (country) within the next 24 months\n47. Known or suspected allergy to semaglutide, tirzepatide, liraglutide, excipients, or related products\n48. Previous participation in this trial and got randomized to one of the study groups but did not proceed.\n49. Hospitalization due to COVID-19 within 2 months prior to screening.\n50. Platelet count \\\u003C80,000\n51. International Normalized Ratio (INR) \\>1.7\n52. Child-Pugh score B or C\n53. MELD score ≥15\n54. Upper endoscopy showing gastroesophageal varices\n55. Upper endoscopy showing more than mild portal hypertensive gastropathy\n56. Liver vascular ultrasound (duplex ultrasonography) showing significant portal hypertension characterized by dilated portal vein (\\>13 mm), biphasic or reverse flow in the portal vein, enlarged paraumbilical veins, splenorenal collaterals, or dilated left and short gastric veins.\n\n    Note: Negative findings on upper endoscopy and liver duplex ultrasound (done within one year of the first study visit for both tests) are necessary to establish eligibility for the FLAMES.\n    * Ruling out clinically significant portal hypertension is particularly important in patients with a liver stiffness ≥20 kPa or with a platelet count \\\u003C150,000 per μL or with a (historical) liver biopsy showing cirrhosis.\n    * A subset of patients without having upper endoscopy and liver duplex ultrasound can be eligible for enrollment if their:\n\n      * liver stiffness (by transient elastography using FibroScan®) is between 12 and 15 kPa and their platelet count is \\>150,000 per μL, or\n      * a (historical) liver biopsy showing absence of cirrhosis, or\n      * a (historical) HVPG \\\u003C 5 mmHg\n57. Cross-sectional abdominal imaging (if available historically) indicating presence of large portosystemic collaterals or ascites\n\n    • Splenomegaly alone (in the absence of other radiological and laboratory findings) is not considered to be a sign of clinically significant portal hypertension and is not an exclusion criterion.\n58. HVPG ≥ 12 mmHg (if available historically or if measured at the time of de novo liver biopsy)\n59. Liver biopsy characteristics:\n\n    * F0 in de novo biopsy; Enrollment cap of 20% for F1 in de novo biopsy.\n    * F0 and F1 in historical liver biopsy\n    * Absence of all three components of MASH (steatosis, hepatocyte ballooning, and lobular inflammation) in patients with F1, F2, and F3\n    * Absence of steatosis (\\\u003C5%) in patients with F4\n    * Diagnosis other than MASH","75 Years",{"count":199,"type":20},120,[201],"PHASE4","Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma. Patients with MASH are also at risk for cardiovascular disease and mortality. There is no universally approved medication for MASH. Weight loss remains the cornerstone of MASH treatment.\n\nPatients meeting the inclusion and exclusion criteria and who give informed consent will be enrolled in the trial and undergo the baseline liver biopsy (if none available). Approximately 120 patients with MASH and liver fibrosis (F1-F4 in baseline liver biopsy) will be randomized in a 1:1 ratio to metabolic surgery or medical treatment (incretin-based therapies ± other medical therapies for MASH) and followed for 2 years at which time a repeat liver biopsy will be performed for the assessment of the primary end point.",[204,205,206,207,208],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Non-Alcoholic Fatty Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Liver Fibrosis","Obesity","2026-07-29",{"date":211,"type":31},"2026-07-31",{"date":213,"type":31},"2024-07-11",{"date":215,"type":20},"2029-12-31",{"name":217,"class":187},"The Cleveland Clinic",22,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100540241","interstellar---international-study-evaluating-lupus-outcomes-after-anifrolumab-real-world-use-100540241","NCT06314282","INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use","INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice","INTERSTELLAR","Inclusion Criteria:\n\n1. Aged 18 years or older at study enrolment.\n2. Fulfilled the 2019 EULAR\u002FACR criteria1 for SLE at the time of study entry.\n3. Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label.\n4. It is important to note that a physician decision to prescribe anifrolumab will need to occur prior to any study-related discussion.\n5. In countries where prescription reimbursements are authorized on a case-by-case basis, authorization (ie, patient access to treatment) will be required for study entry.\n6. Provided informed consent to participate in the study.\n7. Willing and able to participate in all required study evaluations and procedures.\n\nExclusion Criteria:\n\n1. Currently participating in an anifrolumab early access\u002Fcompassionate use program or an interventional clinical trial with an investigational product.\n2. Previous exposure to anifrolumab as part of a clinical trial or early access program.\n3. Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \\[MMF\\]\u002Fcyclophosphamide \\[CYC\\] + high dose steroids), isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus.\n4. Any other condition which the investigator deems to limit a patient's ability to understand the informed consent or complete the PROs.",{"count":19,"type":20},"INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion\u002Fexclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.",[230],"Systemic Lupus Erythematosus (SLE)",[232,233,234,235,236],"SLE","Systemic lupus erythematosus","autoimmune disease","Lupus","Anifrolumab","2026-07-16",{"date":239,"type":31},"2026-07-17",{"date":241,"type":31},"2024-10-22",{"date":243,"type":20},"2027-12-31",{"name":245,"class":38},"AstraZeneca",32,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":51,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":166},"100637988","tirzepatide-titration-to-reduce-side-effects-in-individuals-with-obesity-100637988","NCT07574723","Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity","Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity","TiTRE","Inclusion Criteria:\n\n1. Adults aged 18 years and older\n2. A diagnosis of obesity (BMI ≥ 27 kg\u002Fm2) at screening with self-reported unsuccessful dietary efforts to lose weight.\n3. No diagnosis of diabetes mellites.\n4. Able to understand and sign the consent form\n5. Able to undergo DEXA scan.\n\nExclusion Criteria:\n\n* 1\\. History of type 1 or type 2 diabetes mellites. 2. Obesity-related:\n\n  * A self-reported change in body weight \\>5 kg (11 lbs) within 90 days before screening irrespective of medical records.\n  * Treatment with any medication for the indication of obesity within the past 90 days before screening.\n  * Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and\u002For abdominoplasty, if performed \\>1 year before screening; (2) lap banding, if the band has been removed \\>1 year before screening; (3) intragastric balloon, if the balloon has been removed \\>1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \\>1 year before screening.\n  * Uncontrolled thyroid disease, defined as thyroid stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL as measured by the central laboratory at screening.\n\n    3\\. Mental health:\n  * History of major depressive disorder within 2 years before screening.\n  * Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).\n  * A Patient Health Questionnaire-9 score of ≥15 at screening.\n  * A lifetime history of a suicidal attempt.\n  * Suicidal behavior within 30 days before screening. 4. General safety:\n  * Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown\u002Funspecified content within 90 days before screening.\n  * Presence of acute pancreatitis within the past 180 days prior to the day of screening.\n  * History or presence of chronic pancreatitis.\n  * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n  * Renal impairment measured as estimated glomerular filtration rate value of \\\u003C15 mL\u002Fmin\u002F1.73 m2 as defined by KDIGO 2012 by the central laboratory at screening.\n  * History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n  * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.\n  * Subject presently classified as being in New York Heart Association Class IV.\n  * Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.\n  * Known or suspected abuse of alcohol or recreational drugs.\n  * Known or suspected hypersensitivity to trial product(s) or related products.\n  * Previous participation in this trial. Participation is defined as signed informed consent.\n  * Participation in another clinical trial within 90 days before screening.\n  * Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.\n  * Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","100 Years",{"count":257,"type":20},68,[53],"The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. The main questions it aims to answer are:\n\n1. Does flexible, symptom-guided titration reduce nausea and vomiting compared with standard per-label titration?\n2. Does flexible titration achieve weight loss comparable to standard titration?\n\nResearchers will compare standard per-label titration with a click-based, symptom-guided titration approach to assess differences in tolerability and treatment effectiveness.\n\nParticipants will:\n\n* Be randomly assigned to standard or flexible tirzepatide titration\n* Use a click-based dosing method that allows small dose increases based on tolerability (flexible group)\n* Attend study visits over 76 weeks for safety and outcome assessments\n\nThis study addresses the lack of evidence for individualized titration strategies in obesity treatment and aims to improve tolerability, adherence, and long-term treatment outcomes.",[208],"2026-07-07",{"date":263,"type":31},"2026-07-08",{"date":265,"type":31},"2026-05-15",{"date":215,"type":20},{"name":268,"class":187},"Dasman Diabetes Institute",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":276,"targetDuration":278,"studyType":21,"phases":4,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":298},"100075056","pompe-disease-registry-protocol-100075056","NCT00231400","Pompe Disease Registry Protocol","Pompe Disease Registry","Inclusion Criteria:\n\nAll patients with a confirmed diagnosis of Pompe disease who have signed the informed consent and authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as documented GAA enzyme deficiency from blood, skin, or muscle tissue and\u002For documentation of 2 GAA gene mutations.\n\nExclusion Criteria:\n\nThere are no exclusion criteria in this Registry",{"count":277,"type":20},2000,"5 Years","The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development\u002Freimbursement, and for other research and non-research related purposes.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Pompe disease population.\n* To evaluate the long-term effectiveness of alglucosidase alfa.",[281,282],"Glycogen Storage Disease Type II","Pompe Disease",[284,285,282,286,287,288],"Glycogen Storage Disease Type II (GSD-II)","GSD-II","Pompe Disease (late-onset)","Acid Maltase Deficiency Disease","Glycogenosis II","2026-06-19",{"date":291,"type":31},"2026-06-23",{"date":293,"type":31},"2004-09-15",{"date":295,"type":20},"2034-01-31",{"name":297,"class":38},"Genzyme, a Sanofi Company",272,{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100597965","a-multicenter-observational-study-to-understand-the-clinical-characteristics-treatment-patterns-and-access-to-novel-therapies-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-mea-region-100597965","NCT07065344","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed\u002FRefractory Patients in the Middle East & Africa (MEA) Region.","DOMAIN","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older at diagnosis.\n2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and\u002For histopathological diagnosis.\n3. For Cohort 1: DLBCL patients who are eligible to start treatment\\* according to the investigator's decision.\n4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy.\n5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision\n2. Patients with concurrent active malignancies other than DLBCL.\n3. Patients who are actively participating in any other clinical trial.",{"count":142,"type":20},"Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of NHL, accounting for 30%-40% of cases2. DLBCL is an aggressive malignancy with heterogeneous biology and behavior. Disease risk stratification and treatment planning involve various patient and clinical characteristics (e.g., age, stage, and tumor bulk), prognostic indices (e.g., International Prognostic Index (IPI) score), and gene expression profiling. Patients typically present with nodal or extranodal disease, usually exhibiting rapid tumor growth and symptoms that are highly dependent upon the tumor localization.\n\nThe diagnosis and subtyping of DLBCL have significantly advanced, from morphological assessment of tissue slide to numerous ancillary tests, including immunophenotyping performed by immunohistochemistry (IHC), cytogenetics, and detailed molecular testing to classify the disease based on cell of origin (COO). With the advent of novel therapeutic options, molecular subtyping of DLBCL at diagnosis is expected to allow prognostic stratification of patients into distinct subgroups. This stratification could provide a preclinical rationale for therapeutic targeting the involved pathways and paving the application of personalized treatment.\n\nDLBCL is a potentially curable disease with an overall 60-70% chance of achieving durable complete remission (CR) with the currently used standard first-line immunochemotherapy. However, 30-40% of patients are either refractory to first-line treatment or experience relapse and eventually will die of disease progression7. Although high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is the recommended SOC for eligible patients in the second-line setting based on results from the pivotal PARMA study, real-world SOC in this setting remains less clearly defined.\n\nPatients not cured with ASCT or ineligible to ASCT or refractory to salvage chemotherapy may be considered for Chimeric Antigen Receptor (CAR) T cell therapy targeting CD1910. Although ASCT and CAR-T cell therapy offer patients an opportunity for durable remission, many patients may not be eligible for ASCT or CAR-T cell therapy or relapse after these treatments. In the last decade, the investigation of novel antigens, which can be targeted by immunotherapy and identified to eliminate malignant cells regardless of their molecular pathogenesis, has been constantly pursued.\n\nThis study aims to address this need by examining the demographic, clinical characteristics, and treatment patterns and exploring access to novel therapies for diffuse large B-cell lymphoma (DLBCL) patients, both treatment naïve and relapsed\u002Frefractory patients, in the Middle East and Africa (MEA) region.",[310,311],"Hematology","Diffused Large B Cell Lymphoma",[311],"2026-06-17",{"date":315,"type":31},"2026-06-18",{"date":317,"type":31},"2025-07-23",{"date":319,"type":20},"2027-01-31",{"name":245,"class":38},21,{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":278,"studyType":21,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":218},"100472368","blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-international-registry-100472368","NCT05430971","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry","Inclusion Criteria:\n\n* Diagnosis of BPDCN\n* Signed informed consent form for prospective patients\n\nExclusion Criteria:\n\n\\-",{"count":19,"type":20},"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.",[331],"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","2026-06-04",{"date":334,"type":31},"2026-06-05",{"date":336,"type":31},"2022-07-01",{"date":338,"type":20},"2032-07",{"name":340,"class":187},"Immune Oncology Research Institute",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":51,"phases":351,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":362,"locationsCount":166},"100584161","lean-mass-preservation-with-resistance-exercise-and-protein-during-semaglutidetirzepatide-therapy-100584161","NCT06885736","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide\u002FTirzepatide Therapy","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy (LEAN-PREP Study)","LEAN-PREP","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years\n* BMI \\>\u002F= 27 kg\u002Fm2\n\nExclusion Criteria:\n\n* Currently or in the past 6 months participating in any vigorous aerobic activity (\\>1h per week) or any resistance exercise.\n* BP of 160\u002F100mmHg or higher\n* Any known medical condition that prevents participants from exercising safely\n* A personal or family history of medullary thyroid carcinoma\n* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n* History of chronic or acute pancreatitis\n* History of proliferative diabetic retinopathy or diabetic maculopathy\n* History of ketoacidosis or hyperosmolar state\u002Fcoma\n* History of severe hypoglycaemia and\u002For hypoglycaemia unawareness within last 6 months\n* Clinically significant gastric emptying abnormality or have undergone or plan to undergo gastric bypass or restrictive bariatric surgery or chronically taking drugs that directly affect GI motility\n* Any of the following CV conditions in last 2 months: acute MI, stroke or hospitilisation due to CHF\n* History of NYHA IV CHF\n* Acute or chronic hepatitits, signs and symptoms of any liver disease other than NAFLD, ALT \\> 3 times the upper limit of normal\n* eGFR \\\u003C45mL\u002Fmin\u002F1.73m2\n* Significant uncontrolled endocrine abnormaility in the opinion of clinical investigator\n* Evidence of active autoimmune abnormality that is likely to requite systemic glucocorticoid treatment in the next 12 months\n* Had or waiting for an organ transplant\n* History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years\n* Any other aspect of history or condition that may limit the ability of the patient to complete the study\n* Having been treated with prescription drugs that promote weight loss in the last 3 months\n* Receiving chronic systemic glucocorticoid therapy within last month",{"count":350,"type":20},232,[53],"The aim of the current study is to determine whether resistance exercise and\u002For protein intake can preserve lean mass and improve physical function in patients with obesity initiating semaglutide\u002Ftirzepatide therapy. To achieve this aim the study will have the following objectives.\n\nIn people with obesity initiating semaglutide\u002Ftirzepatide therapy\n\n1. Form a PPI group to refine the study protocol and establish study materials,\n2. Quantify the effects of a pragmatic resistance exercise intervention and\u002For increasing protein intake on lean mass and physical function during semaglutide\u002Ftirzepatide induced weight loss,\n3. Establish whether the resistance exercise intervention and\u002For increasing protein intake has concomitant benefits on glycaemic control, lipids, liver function, quality of life, physical activity and sleep during semaglutide\u002Ftirzepatide induced weight loss.\n\nThe participants will:\n\nBegin their weight loss medication, starting at a low dose and then increasing the dose to maximize weight loss. They will be randomly assigned by a computer to ONE of the following groups and will be followed up to 6-months:\n\n* Control group\n* Protein intake group\n* Muscle strengthening exercise group\n* Muscle strengthening exercise AND protein intake group.",[208],[355],"Obesity, research","2026-04-19",{"date":358,"type":31},"2026-04-21",{"date":360,"type":31},"2025-08-07",{"date":215,"type":20},{"name":268,"class":187},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":370,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":51,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":166},"100600393","phase-4-tirzepatide-use-in-people-with-obesity-and-type-1-diabetes-100600393","NCT07096908","Tirzepatide Use in People With Obesity and Type 1 Diabetes","Treatment With Tirzepatide of the Disease of Obesity in People With Type 1 Diabetes","Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities.\n2. Male or female, adults.\n3. Documented diagnosis of T1DM (per ADA 2024definition\u002Fcriteria) for at least 1 year before screening visit with C-peptide level of less than 0.01nm\u002FL.\n4. Body mass index (BMI) ≥ 27.0 kg\u002Fm2\n5. History of at least one self-reported unsuccessful dietary effort to lose body weight.\n6. Must be using a Continuous Glucose Monitoring (CGM) device for at least 2 months before the screening visit and be willing to wear a CGM device for the duration of the study.\n\nExclusion Criteria:\n\n1. Diabetes related:\n\n   * Glycated hemoglobin (HbA1c) ≥86 mmol\u002Fmol (10%) as measured by the central laboratory at screening.\n   * Treatment with a glucagon-like peptide-1 receptor agonist within 180 days before screening.\n   * Preproliferative or proliferative retinopathy\n   * Experienced diabetic ketoacidosis within 6 months of screening visit.\n   * Experienced severe hypoglycemia (Level 3) within 6 months of screening visit.\n2. Obesity-related:\n\n   * A self-reported change in body weight \\>5 kg (11 lbs) within 90 days before screening irrespective of medical records.\n   * Treatment with any medication for the indication of obesity within the past 90 days before screening.\n   * Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and\u002For abdominoplasty, if performed \\>1 year before screening; (2) lap banding, if the band has been removed \\>1 year before screening; (3) intragastric balloon, if the balloon has been removed \\>1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \\>1 year before screening.\n   * Uncontrolled thyroid disease, defined as thyroid stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL as measured by the central laboratory at screening.\n3. Mental health:\n\n   * History of major depressive disorder within 2 years before screening.\n   * Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).\n   * A Patient Health Questionnaire-9 score of ≥15 at screening.\n   * A lifetime history of a suicidal attempt.\n   * Suicidal behavior within 30 days before screening.\n   * Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale within the past 30 days before screening.\n4. General safety:\n\n   * Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown\u002Funspecified content within 90 days before screening.\n   * Presence of acute pancreatitis within the past 180 days prior to the day of screening.\n   * History or presence of chronic pancreatitis.\n   * Calcitonin ≥100 ng\u002FL as measured by the central laboratory at screening.\n   * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n   * Renal impairment measured as estimated glomerular filtration rate value of \\\u003C15 mL\u002Fmin\u002F1.73m2 as defined by KDIGO 2012 by the central laboratory at screening.\n   * History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n   * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.\n   * Subject presently classified as being in New York Heart Association Class IV.\n   * Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.\n   * Known or suspected abuse of alcohol or recreational drugs.\n   * Known or suspected hypersensitivity to trial product(s) or related products.\n   * Previous participation in this trial. Participation is defined as signed informed consent.\n   * Participation in another clinical trial within 90 days before screening.\n   * Other subject(s) from the same household participating in any semaglutide trial.\n   * Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.\n   * Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","21 Years",{"count":372,"type":20},60,[201],"Tirzepatide, a gut hormone-based medication, has shown promising results in treating obesity, with \\~22% weight loss and mild side effects. However, patients with type 2 diabetes typically experience only about 15% weight loss with tirzepatide, despite tolerating the medication well. Its effects in people with both obesity and type 1 diabetes remain largely unknown.\n\nAlthough tirzepatide is not approved for glycemic control in type 1 diabetes, it is licensed for obesity treatment in Gulf and Europe. In Kuwait, more than a quarter of people with type 1 diabetes also have obesity, presenting a unique opportunity to study tirzepatide's impact.\n\nThis randomized, double-blind controlled trial will evaluate the safety and efficacy of tirzepatide in patients with type 1 diabetes and obesity, comparing usual care with the maximum tolerable dose of tirzepatide to assess its impact on weight loss. The findings may help address important safety concerns and have the potential to inform and influence future clinical practice.",[376,208],"Type1diabetes",[378,379,380,381],"T1D","tirzepatide","weight loss","obesity","2026-04-15",{"date":384,"type":31},"2026-04-20",{"date":386,"type":31},"2025-07-31",{"date":388,"type":20},"2028-08-01",{"name":268,"class":187},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":397,"targetDuration":399,"studyType":21,"phases":4,"briefSummary":400,"conditions":401,"keywords":406,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":414},"100084590","international-collaborative-gaucher-group-icgg-gaucher-disease-registry--pregnancy-sub-registry-100084590","NCT00358943","International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","Gaucher Disease Registry Protocol","Inclusion Criteria:\n\nICGG Gaucher Registry\n\n* All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and\u002For mutation in the β-glucocerebrosidase gene.\n* For all patients, appropriate patient authorization will be obtained.\n\nGaucher Pregnancy Sub-registry:\n\n* be enrolled in the ICGG Gaucher Registry.\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nExclusion Criteria:\n\n\\- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.",{"count":398,"type":20},12000,"12 Months","The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.\n\nThe objectives of the Registry are:\n\n* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.\n* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.\n* To characterize the Gaucher disease population.\n* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.\n\nGaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.",[402,403,404,405],"Gaucher Disease","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease",[402,404],"2026-04-13",{"date":409,"type":31},"2026-04-14",{"date":411,"type":31},"1991-04-01",{"date":295,"type":20},{"name":297,"class":38},318,{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":370,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":51,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":166},"100620709","a-comparative-study-of-intradialytic-vs-pre-dialysis-physical-therapy-interventions-in-individuals-undergoing-hemodialysis-a-randomized-controlled-trial-100620709","NCT07361146","A Comparative Study of Intradialytic vs. Pre-Dialysis Physical Therapy Interventions in Individuals Undergoing Hemodialysis: A Randomized Controlled Trial","A Comparative Study of Intradialytic Versus Pre-Dialysis Physical Therapy Interventions in Individuals Undergoing Hemodialysis: A Randomized Controlled Trial","DIAL-PT","Inclusion Criteria:\n\n* Adults aged between 21 and 65 years.\n* Diagnosed with end-stage renal disease (ESRD).\n* Undergoing maintenance hemodialysis for at least 3 months.\n* Medically stable and cleared by the nephrologist to participate in moderate physical exercise.\n* Able to understand and follow verbal instructions and provide informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension, recent myocardial infarction, or unstable angina.\n* Severe musculoskeletal, neurological, or cardiovascular disorders that limit physical activity.\n* Active infection, fever, or open wounds.\n* Recent hospitalization within the past month.\n* Participation in any other structured exercise program within the last 3 months.","65 Years",{"count":425,"type":20},72,[53],"This randomized controlled trial aims to compare the effectiveness of two different timings of physical therapy for individuals undergoing hemodialysis: intradialytic (during dialysis) and pre-dialysis (before dialysis). The study seeks to determine which approach provides better improvements in physical function, quality of life, and biochemical outcomes such as hemoglobin and electrolyte levels.\n\nA total of 72 adult participants with end-stage renal disease (ESRD) receiving hemodialysis will be randomly assigned to one of two groups. Both groups will receive standardized educational sessions on the benefits and safety of exercise before beginning the intervention. Participants in the intradialytic group will perform supervised exercises during their dialysis sessions, while those in the pre-dialysis group will complete similar exercises before their dialysis sessions. Each participant will undergo the intervention twice per week for 12 weeks.\n\nPrimary outcomes include physical function, assessed using the Six-Minute Walk Test and the Five Times Sit-to-Stand Test. Secondary outcomes include hemoglobin levels, electrolyte balance, and health-related quality of life measured by the KDQOL questionnaire. The study will be conducted at Mubarak Al-Abdullah Al-Jaber Al-Sabah Dialysis Center, Kuwait, following ethical approval from the Ministry of Health Research Ethics Committee.\n\nThe results are expected to inform best practices for integrating physical therapy into dialysis care to enhance the health, safety, and well-being of individuals undergoing hemodialysis.",[429,430,431,432],"End-stage Renal Disease (ESRD)","Chronic Kidney Disease","Hemodialysis Patients","Physical Rehabilitation During Dialysis","2026-01-14",{"date":435,"type":31},"2026-01-22",{"date":437,"type":31},"2025-03-02",{"date":439,"type":20},"2027-06-02",{"name":441,"class":165},"Mohammad Arian",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":51,"phases":450,"briefSummary":451,"conditions":452,"keywords":456,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":166},"100613212","the-effect-of-balance-focused-exercise-programme-in-enhancing-the-solus-muscle-activation-during-gait-initiation-for-people-with-parkinson-disease-100613212","NCT07263646","The Effect of Balance-focused Exercise Programme in Enhancing the Solus-muscle Activation During Gait Initiation for People With Parkinson Disease","Inclusion Criteria:\n\n* participants diagnosed by their neurologist with Parkinson's disease (moderate to severe stage)\n* stable on anti-Parkinson's drugs\n* able to walk independently without a frame or walking stick.\n* Able to walk for more than 10 mins unaided\n* without cognitive disability (Able to follow simple instructions and communicate, orally),\n* have good vision (with or without corrective aids)\n\nExclusion Criteria:\n\n* are pregnant\n* cardiac problems exacerbated by exercise\n* currently complaining of joint or muscle problems that affect walking ability\n* known to have neurological conditions (other than Parkinson) that affect walking ability\n* uncorrected hearing or vision problems\n* history of severe motion sickness\n* history of vestibular or balance problems\n* an active skin condition that could be irritated by contact with sticky tape.",{"count":449,"type":20},80,[53],"Gait initiation (GI) is a crucial component of walking that requires a balanced muscle activity and postural stability. GI could be challenging for people with neurological condition such as people with Parkinson (PWP), where GI is usually impaired. The purpose of this study is determining effectiveness of comprehensive, balanced-focused exercise programme in controlling the activation of Solus-muscle in people with Parkinson disease. We hypothesise that balance-focus exercise programe could improve Solus-muscle activation during GI.\n\nstudy type: this is a parallel group prospective (10 weeks) randomised single-blinded controlled trial conduct in Kuwait.\n\nParticipant: People with Parkinson, who met the inclusion criteria.",[453,454,455],"Parkinson Disease","Gait Disorders","Gait Balance",[457,458,459,460],"gait initiation","Parkinson disease","rehabilitation","balance-focus exercise","2025-12-03",{"date":463,"type":31},"2025-12-10",{"date":435,"type":20},{"date":466,"type":20},"2028-12-22",{"name":468,"class":165},"Ministry of Health, Kuwait",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":11,"sex":476,"minAge":477,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":51,"phases":480,"briefSummary":481,"conditions":482,"keywords":486,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":166},"100488603","effects-of-fall-prevention-program-on-the-number-of-falls-among-elderly-following-total-knee-replacement-100488603","NCT05642260","Effects of Fall Prevention Program on the Number of Falls Among Elderly Following Total Knee Replacement","The Short- and Long-term Effects of Fall Prevention Program on the Number of Falls Among Elderly Following Total Knee Replacement: a Pragmatic Single-blinded Randomized Controlled Trial.","Inclusion Criteria:\n\n* Female gender.\n* Aged 60 years and older.\n* Diagnosed with primary osteoarthritis of the knee.\n* Underwent unilateral TKR.\n\nExclusion Criteria:\n\n* revision TKR surgery\n* history of systemic inflammatory conditions (i.e., rheumatoid arthritis, Lupus erythematosus),\n* neurological disorders (i.e., multiple sclerosis, Parkinson's disease, stroke)\n* lower limb surgery\u002Ftrauma in the past 12 months\n* have cognitive and\u002For vision impairments\n* post-surgical complications (e.g., infection, intraoperative fracture)\n* any health condition that may preclude them from undertaking physiotherapy.","FEMALE","60 Years",{"count":479,"type":20},90,[53],"the aim of the proposed research is to investigate the short and long-term effects of integrating a comprehensive fall prevention programme into conventional physiotherapy on the number of falls, balance, and functional ability among elderly following TKR. the investigator hypothesize that conventional physiotherapy integrated with a fall prevention program is more effective than conventional physiotherapy alone in improving balance and functional ability and preventing the occurrence of falls among elderly following TKR.\n\nStudy type: The proposed study is a parallel group prospective (24 weeks) randomised single-blinded pragmatic controlled trial.\n\nParticipants: Older adults operated for TKR at Al-Razi orthopedic hospital, who met the inclusion criteria.",[483,484,485],"Fall","Osteo Arthritis Knee","Total Knee Replacement",[487,488,489,490,459],"fall","older people","fall prevention","TKR","2025-12-02",{"date":493,"type":31},"2025-12-09",{"date":495,"type":31},"2023-01-08",{"date":497,"type":20},"2026-09-08",{"name":468,"class":165},{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":51,"phases":506,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":523},"100586997","phase-4-can-the-addition-of-pioglitazone-to-sglt2-inhibitor-in-type-1-diabetic-patients-amplify-the-decrease-in-hba1c-and-prevent-the-increase-in-plasma-ketone-concentration-100586997","NCT06922656","Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","Inclusion Criteria:\n\n\\- 1) Age \\>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.\n\n4\\) Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U\u002Fkg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml\u002Fmin. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program\n\nExclusion Criteria:\n\n* 1\\) Age \\>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.\n\n  4\\) Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U\u002Fkg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml\u002Fmin. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program",{"count":372,"type":20},[201],"Previous data from our clinical trial has demonstrated that the combination of dapagliflozin plus pioglitazone cause robust decrease in the plasma glucose concentration without significant increase in plasma ketone concentration in subjects with T1DM receiving multiple insulin injections or insulin pump. Although patients receiving insulin therapy with pump have participated in the study, none has insulin delivered in automated pump (780 pump) which automatically adjusts the rate of insulin infusion based upon the measured plasma glucose concentration. Although automated insulin pumps have been introduced to practice only last year, they are gaining popularity in the care of T1DM patients worldwide. The aim of this amendment is to demonstrate the efficacy (decrease in HbA1c) and safety (no significant increase in plasma ketone concentration) of combination of dapagliflozin plus pioglitazone in T1DM patients receiving insulin therapy with automated insulin pump.",[56],[510,511,512,513,514],"Ketoacidosis","Hypoglycemia","Glucose Control","SGLT2 Inhibitors","Pioglitazone","2025-08-24",{"date":517,"type":31},"2025-08-29",{"date":519,"type":20},"2025-09-15",{"date":521,"type":20},"2027-01-15",{"name":268,"class":187},3,{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":16,"minAge":531,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":51,"phases":535,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":166},"100591723","structured-education-program-and-glycemic-control-in-adolescents-with-type-1-diabetes-100591723","NCT06984133","Structured Education Program and Glycemic Control in Adolescents With Type 1 Diabetes","Evaluating the Effectiveness of a Structured Educational Program on Glycemic Control in Adolescents With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Arab adolescents\n* Males and females aged 11 to 14 years.\n* Have been diagnosed with type 1 diabetes for at least 6 months.\n* Wearing a continuous glucose monitor (CGM).\n* Individuals and their parents must be able to join the entire duration of the study.\n* Individuals and their parents must voluntarily provide consent and assent.\n\nExclusion Criteria:\n\n* Presence of learning disabilities or any known psychological issues.\n* Attendance at any diabetes education or carbohydrate counting programs within the six months preceding the study.","11 Years","14 Years",{"count":534,"type":20},128,[53],"Type 1 diabetes is becoming more common in Kuwaiti and Arab adolescents. Many young people with this condition struggle to keep their blood glucose levels under control, which can lead to diabetes-related complications and affect their quality of life.\n\nThe goal of this clinical trial is to evaluate the effectiveness of a structured educational program on glycemic control among Arab adolescents with type 1 diabetes aged 11 to 14 years.\n\nParticipants will be randomly assigned to one of two groups. The intervention group will receive the structured education program, and the control group will continue with standard care.\n\nAll participants will undergo assessments that include:\n\n* collecting demographic and diabetes management data\n* measuring weight and height\n* measuring HbA1c levels and lipid profile\n* filling out questionnaires on quality of life, carbohydrate and insulin dosing knowledge, physical activity\n* collecting dietary intake\n* providing AGP report\n\nParticipants in the intervention group will additionally be required to:\n\n* attend the program for 4 consecutive days, one day for parents and three days for children\n* fill out 3-day food diary records during the program\n* attend a refresher course after 6 months\n\nParticipants in the control group will have the opportunity to participate in the program after approximately six months.",[538,539],"Type 1 Diabetes (T1D)","Type 1 Diabetes Mellitus (T1DM)",[154,541,542,543,544,545,546,547,548],"Glycemic control","Type 1 diabetes","Carbohydrate counting","Arab adolescents","Structured education","Adolescents","Diabetes education program","HbA1c","2025-05-14",{"date":551,"type":31},"2025-05-22",{"date":553,"type":20},"2025-05-18",{"date":555,"type":20},"2028-05-18",{"name":268,"class":187},{"id":558,"slug":559,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":476,"minAge":4,"maxAge":4,"enrollmentInfo":564,"targetDuration":565,"studyType":21,"phases":4,"briefSummary":566,"conditions":567,"keywords":571,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":166},"100569438","improving-outpatient-endometrial-biopsy-results-100569438","NCT06694246","Improving Outpatient Endometrial Biopsy Results","Outpatient Endometrial Biopsy Results; a Quality Improvement Project.","Inclusion Criteria:\n\n* All patients undergoing outpatient endometrial biopsy in the specified time interval (11\u002F2024- 4\u002F2025) will be included.\n\nExclusion Criteria:\n\n* Could not obtain the sample due to patient physicals, anxiety (patient decline), cervical stenosis, or severe bleeding",{"count":130,"type":20},"6 Months","Pipelle is the most commonly used outpatient endometrial biopsy device. Pipelle endometrial biopsy can diagnose 90% of endometrial cancer cases. Pipelle endometrial biopsy is one of the first-line diagnostic procedures for women presenting with abnormal peri- and post-menopausal vaginal bleeding.\n\nInsufficient samples are obtained in 5-23% of cases. In Adan Hospital, a retrospective analysis of all outpatient endometrial samples sent to the histopathology department from April- to October 2024 study showed an insufficient sample percentage of 32% This may be attributed to factors such as patients, equipment, and physicians.\n\nThis project aims to improve the endometrial biopsy results by Identifying these factors in the Adan hospital setting, Implementing measures to modify these factors, and finally re-auditing the endometrial biopsy results after six months.",[568,569,570],"Histopathology","Screening Tool","Techniques",[572,573,574,575,576,577],"Pipelle","Endometrial biopsy","histopathology","endometrial sampling","screening","outpatient","2024-12-02",{"date":580,"type":31},"2024-12-04",{"date":582,"type":31},"2024-11-01",{"date":584,"type":20},"2025-04-30",{"name":586,"class":187},"Cairo University",{"id":588,"slug":589,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":11,"sex":16,"minAge":594,"maxAge":140,"enrollmentInfo":595,"targetDuration":4,"studyType":51,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":607,"leadSponsor":609,"locationsCount":166},"100564715","a-pilot-study-to-assess-the-impact-of-breath-awareness-using-pyramid-on-symptoms-of-anxiety-and-depression-in-people-with-t2dm-100564715","NCT06632782","A Pilot Study to Assess the Impact of Breath Awareness Using Pyramid on Symptoms of Anxiety and Depression in People with T2DM","BAPD","Inclusion Criteria: • More than 1 year of T2DM diagnosis\n\n* T2DM with HbA1c greater than 5.7 and less than 9.5%\n* T2DM patients, age greater than 30 years and on oral hypoglycaemic agents or on insulin\n* No cardiac problems\n* Score 8.0 and above as per the anxiety and depression questionnaires.\n* Able to be aware of breath and provide written informed consent.\n\nExclusion Criteria:\n\n* T1DM patients\n* On antidepressant drugs\n* Bipolar disorders\n* Any acute coronary events in the past 6 months\n* Any acute renal diseases including transplant or dialysis.\n* Artificial pacemaker\n* Any breath awareness or yoga course within 6 months.\n* Pregnancy","30 Years",{"count":596,"type":20},152,[53],"Diabetes mellitus is rampant in the Middle East. It is a psychologically and behaviorally demanding disease; psychosocial factors are relevant to nearly all aspects of its management. Moreover, depression and diabetes are bidirectionally connected. Those with depression are at risk of developing diabetes and those with comorbid diabetes are at risk of developing depressive symptoms. Research findings have demonstrated that depression and anxiety are more common in patients with diabetes than in the general population, atleast 15 % have clinical depression. In addition, the recent COVID- 19 pandemic has fueled the burden by increasing fear, anxiety, and depression among people with T2DM due to susceptibility to long-term complications. In Kuwait, a recent survey found the prevalence of depression to be 29% and diabetes distress to be 14%. Thus, there is a dire need to address this challenging problem. In the recent past, mindfulness-based intervention such as Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT,) and yoga have emerged as unique tools for reducing a wide range of psychological disorders. These tools positively impact hormone regulation and have a beneficial effect on cognitive function and increased parasympathetic activity. The positive impact of mindfulness is assumed to be amplified if a pyramid structure with geometry similar to the pyramid of Giza is used for practice. Not much human research has been performed to demonstrate that pyramid energy along with mindfulness can be a tool to combat psychological disorders. However, few studies on animal models provided evidence of the potential beneficial effect of pyramid structure in reducing stress. Previous pilot study conducted using only yoga as an intervention indicated significant improvement in anxiety, depression, and quality of life in people with T2DM. However, there was no change in participants' glycemic control. In this pilot study, investigator will assess whether pyramid breath awareness can alleviate symptoms of depression and anxiety in people with T2DM.",[600],"Depression, Anxiety",[602],"depression","2024-10-16",{"date":605,"type":31},"2024-10-18",{"date":582,"type":20},{"date":608,"type":20},"2026-12-31",{"name":268,"class":187},{"id":611,"slug":612,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":47,"sex":16,"minAge":370,"maxAge":197,"enrollmentInfo":617,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":618,"conditions":619,"keywords":623,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":166},"100524987","kuwait-adult-diabetes-epidemiological-multidisciplinary-kadem-program-100524987","NCT06115876","Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program","KADEM","Inclusion Criteria:\n\nPeople who participated in the original KDEP study. People with prediabetes. Type 2 Diabetes patients.\n\nExclusion Criteria:\n\nPeople are unwilling to sign the consent form. Pregnant women.",{"count":277,"type":20},"Kuwait and the Gulf Region lack large longitudinal studies that identify risk factors dictating the onset of prediabetes and the progression to diabetes. The Kuwait Diabetes Epidemiology Program (KDEP), previously carried out at Dasman Diabetes Institute, was designed to develop a research dataset providing a random sampling of the Kuwaiti population. The dataset contained primarily epidemiology data for healthy, prediabetic and diabetic individuals; and was designed to serve as a resource for research and prevention programs on obesity, diabetes, and metabolic syndrome. The KDEP data supported research studies at DDI to delineate risk factors for metabolic disease from the views of genetics, biochemistry, immunology and epidemiology. One of the main limitations of the KDEP study was that it only captured a cross-sectional view of the participants in terms of diabetes status as well as lack of extensive phenotyping. In the current study, the investigators aim to perform a follow up on the non-diabetic KDEP cohort participants to enrich it with detailed physiological, genetic, biochemical and environmental data and thereby to establish an association between the development of diabetes and multidimensional risk factors. the investigatorswill also recruit family members of the KDEP and RA2010-005 participants as well as others with family history of diabetes to better identify familial patterns in risk factors. The outcome of this effort will immediately serve as a scientific baseline for developing prevention strategies for the control and management of obesity, diabetes and associated complications such as cardiovascular disease. Given the magnitude of the social and economic burden of diabetes on the Kuwaiti population, longitudinal data from the KDEP Follow-up study should play an important role in establishing the incidence of T2D progression in non-diabetic participants that were enrolled in the initial study as well as of progression to diabetes complications. This will have a positive impact on the population by providing clinicians with data to better target their patient management and by supporting policy and decision-makers in developing comprehensive health promotion programs to control these diseases at the national level.",[620,621,622],"Diabetes Mellitus Type 2, Diabetes Mellitus Type 1","NAFLD - Nonalcoholic Fatty Liver Disease","PreDiabetes",[624,154,625,268,626,627],"Prediabetes","KFAS","Diabetes Prevention","NAFLD","2023-10-30",{"date":630,"type":31},"2023-11-03",{"date":632,"type":31},"2022-05-23",{"date":634,"type":20},"2027-05-23",{"name":268,"class":187},{"id":637,"slug":638,"hasResults":11,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":11,"sex":16,"minAge":644,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":51,"phases":648,"briefSummary":650,"conditions":651,"keywords":654,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":166},"100491128","early-phase-1-central-nervous-system-stimulants-and-physical-function-in-children-with-cerebral-palsy-100491128","NCT05675098","Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy","Effect of Central Nervous System Stimulants on Physical Function in Children With Cerebral Palsy: A Pilot Randomized Controlled Trial","CP","Inclusion Criteria:\n\n* Children diagnosed with spastic diplegic or quadriplegic CP by a physician.\n* Children aged between 7-12 years old.\n* Children with CP classified as level I \\& II based on the gross motor function classification system (GMFCS).\n* Children with CP that are receiving physical therapy for ≥ 3 months.\n\nExclusion Criteria:\n\n* Children that had a seizure attack in the past 6 months\n* Children that have been diagnosed with attention deficit\u002F hyperactivity disorder (ADHD)\n* Children that had any surgery within the last 6 months\n* Children that has lower-extremity contractures determined by the passive range of motion (hips, knees, and ankles)\n* Children that use medications that interfere with spasticity (e.g., Baclofen)","7 Years","12 Years",{"count":647,"type":20},30,[649],"EARLY_PHASE1","The purpose of this study is to determine the effects of Central Nervous System Stimulants, represented by Methylphenidate and Modafinil, compared to placebo control on motor performance in children with Cerebral Palsy. This study will be a triple-masked study per the American Academy of Neurology guidelines for clinical trials.",[652,653],"Neurodevelopmental Disorders","Cerebral Palsy",[655,656,657,658,659,660],"methylphenidate","Modafinil","physical therapy","motor performance","spasticity","physical function","2023-03-07",{"date":663,"type":31},"2023-03-08",{"date":665,"type":20},"2023-05-01",{"date":667,"type":20},"2027-02-01",{"name":669,"class":187},"Kuwait University",""]